Key Takeaways
- • Curium has reset the FTC's 30-day review clock on its $8 billion take-private acquisition of radiopharmaceutical company Lantheus Holdings Inc., signaling a strategic procedural move in the regulatory review process.
- • The deal represents a significant consolidation in the radiopharmaceutical sector, combining two major players in a nuclear medicine-focused space.
- • The FTC clock reset indicates either a request for additional information from the agencies reviewing the transaction or a resubmission of materials, extending the timeline for regulatory approval.
- • As a private equity-backed company, Curium's acquisition of Lantheus would remove a publicly traded competitor from the market and consolidate market share in radiopharmaceuticals.
Summary
Curium, a private equity-backed radiopharmaceutical company, has reset the Federal Trade Commission's 30-day review period for its proposed $8 billion take-private acquisition of Lantheus Holdings Inc., according to a report from Law360 on September 23, 2026. The clock reset represents a procedural development in the regulatory approval process for the transaction, which would consolidate two major participants in the radiopharmaceutical and nuclear medicine sector.
The reset of the FTC's review timeline typically occurs when deal parties submit additional information requested by antitrust authorities or resubmit documentation to address regulatory concerns. This procedural step extends the overall timeline for closing the transaction, as the 30-day review period recommences from the date of resubmission. The move underscores the ongoing nature of federal scrutiny into the proposed combination, though the specific reason for the clock reset has not been detailed in available reporting.
Lantheus Holdings, as a public company in the radiopharmaceutical space, has been the subject of acquisition interest from Curium, which operates with private equity backing. The $8 billion valuation reflects the strategic importance of Lantheus's assets, market position, and revenue generation capabilities within a sector focused on diagnostic and therapeutic nuclear medicine products. The take-private structure would result in Lantheus shareholders receiving an acquisition premium and the company being delisted from public markets.
The FTC's review process remains ongoing as of the reported date, with investors and market participants monitoring the regulatory outcome. Completion of the transaction remains subject to satisfaction of closing conditions, including FTC approval and any conditions or remedies the agency may impose as a result of its competitive analysis of the combined entity's market position.
The reset of the FTC's review timeline typically occurs when deal parties submit additional information requested by antitrust authorities or resubmit documentation to address regulatory concerns. This procedural step extends the overall timeline for closing the transaction, as the 30-day review period recommences from the date of resubmission. The move underscores the ongoing nature of federal scrutiny into the proposed combination, though the specific reason for the clock reset has not been detailed in available reporting.
Lantheus Holdings, as a public company in the radiopharmaceutical space, has been the subject of acquisition interest from Curium, which operates with private equity backing. The $8 billion valuation reflects the strategic importance of Lantheus's assets, market position, and revenue generation capabilities within a sector focused on diagnostic and therapeutic nuclear medicine products. The take-private structure would result in Lantheus shareholders receiving an acquisition premium and the company being delisted from public markets.
The FTC's review process remains ongoing as of the reported date, with investors and market participants monitoring the regulatory outcome. Completion of the transaction remains subject to satisfaction of closing conditions, including FTC approval and any conditions or remedies the agency may impose as a result of its competitive analysis of the combined entity's market position.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.